Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort.

Journal: European urology focus
Published Date:

Abstract

BACKGROUND: Primary robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for men with nonseminomatous germ cell tumor (NSGCT) is an alternative to open RPLND for stage I and select stage II patients.

Authors

  • Jacob Taylor
    NYU Langone Health, New York, NY, USA. Electronic address: Jacob.Taylor@nyulangone.org.
  • Ezequiel Becher
    NYU Langone Health, New York, NY, USA.
  • James S Wysock
    NYU Langone Health, New York, NY, USA.
  • Andrew T Lenis
    University of California Los Angeles, Los Angeles, CA, USA.
  • Mark S Litwin
    University of California Los Angeles, Los Angeles, CA, USA.
  • Jacob Jipp
    Medical College of Wisconsin, Milwaukee, WI, USA.
  • Peter Langenstroer
    Medical College of Wisconsin, Milwaukee, WI, USA.
  • Scott Johnson
    Medical College of Wisconsin, Milwaukee, WI, USA.
  • Marc A Bjurlin
    Department of Urology, New York University, New York, NY, USA.
  • Hung-Jui Tan
    VA/UCLA Robert Wood Johnson Clinical Scholars Program, University of California, Los Angeles, CA; Department of Urology, University of California, Los Angeles, CA.
  • Brian R Lane
    Spectrum Health, Grand Rapids, MI, USA. brian.lane@spectrumhealth.org.
  • William C Huang
    NYU Langone Health, New York, NY, USA.